The immunological network at the site of tumor rejection
- PMID: 2942190
- DOI: 10.1016/0304-419x(86)90009-0
The immunological network at the site of tumor rejection
Erratum in
- Biochim Biophys Acta 1986 Oct 28;865(2):233
Abstract
The tumor mass irrespective of its type or location in the body has long been shrouded in mystery and even today we still have only a tentative handle on its secrets. Attempts to manipulate either the tumor cells per se or host-derived leukocytes have, on the whole, not been successful or at best questionable. The ability of the host to respond immunologically to TSTA is well documented, yet again attempts to manipulate this response have been disappointing. One of the problems has been a lack of knowledge concerning the tumor mass and its constituents, such as the intratumor leukocytes, and the significance of their presence to the biological properties of the neoplasm [8,9,80]. The purpose in studying the immunological network is, in part, to try to assign a function to these cells on the premise that lymphoid elements and macrophages have a potential role to play in recognition of TSTA. The advantage of adoptive immunotherapy model systems is that tumor rejection can be achieved under controlled conditions and this allows an analysis of the immunological network and its individual circuits. At the same time, valuable information on the mechanisms of action during adoptive immunotherapy and how best to improve therapeutic protocols is acquired.
Similar articles
-
Down-regulation of the antitumor immune response.Adv Cancer Res. 1985;45:1-43. doi: 10.1016/s0065-230x(08)60265-1. Adv Cancer Res. 1985. PMID: 2936064 Review. No abstract available.
-
Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors.Cancer Res. 1986 Jul;46(7):3426-30. Cancer Res. 1986. PMID: 2939946
-
Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.J Immunol. 1988 Aug 1;141(3):1047-53. J Immunol. 1988. PMID: 3260908
-
Reverse immunoediting: When immunity is edited by antigen.Immunol Lett. 2016 Jul;175:16-20. doi: 10.1016/j.imlet.2016.04.015. Epub 2016 Apr 27. Immunol Lett. 2016. PMID: 27131431 Review.
-
Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors.Cancer Res. 1990 Apr 15;50(8):2228-33. Cancer Res. 1990. PMID: 2317810
Cited by
-
Detection and characterization of anti-tumour effector cells in Meth-A-bearing mice treated with recombinant human interleukin 2.Clin Exp Immunol. 1989 May;76(2):278-83. Clin Exp Immunol. 1989. PMID: 2788049 Free PMC article.
-
Autonomous expressions of cytokine genes by human lung cancer cells and their paracrine regulation.Jpn J Cancer Res. 1994 Feb;85(2):179-86. doi: 10.1111/j.1349-7006.1994.tb02080.x. Jpn J Cancer Res. 1994. PMID: 8144399 Free PMC article.
-
The immunological mouse mutants nude (nu) and rhino (hrrh) generate cytotoxic effector cells following adoptive immunotherapy but fail to reject a transplanted tumor.Cancer Immunol Immunother. 1988;26(1):35-42. doi: 10.1007/BF00199845. Cancer Immunol Immunother. 1988. PMID: 3257902 Free PMC article.
-
Lysis of human leukemic cells by monocyte-derived macrophages activated with interferon-gamma and interleukin-2.Jpn J Cancer Res. 1989 Jan;80(1):59-64. doi: 10.1111/j.1349-7006.1989.tb02245.x. Jpn J Cancer Res. 1989. PMID: 2496059 Free PMC article.
-
Elevated expression of interleukins in lung adenocarcinomas induced by N-Nitrosobis(2-hydroxypropyl)amine in rats.Jpn J Cancer Res. 2000 Oct;91(10):955-9. doi: 10.1111/j.1349-7006.2000.tb00870.x. Jpn J Cancer Res. 2000. PMID: 11050463 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources